Oculopharyngeal Muscular Dystrophy (OPMD) Market Share

  • Report ID: 5825
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Oculopharyngeal Muscular Dystrophy (OPMD) Market Share

North American Market Forecast

The North America oculopharyngeal muscular dystrophy market estimated to hold the largest revenue share about 36% during the forecast period. The growth of the market can be attributed to the growing frequency of Oculopharyngeal muscular dystrophy disorder in the region. For instance, the highest prevalence rate of Oculopharyngeal muscular dystrophy 1/1000 people can be found in French Canadian population of Quebec Canada. In USA around 1/100,000 people are diagnosed with Oculopharyngeal muscular dystrophy. Furthermore, high health awareness among the population along with easy access to quality healthcare in developed region is attributed to rapid market expansion in the region during the forecast period. In addition to that, the region’s rising technological healthcare industry and expanding expenditure are also anticipated to boost the market growth in the upcoming years.

APAC Market Forecast

The Asia Pacific oculopharyngeal muscular dystrophy market is estimated to the second largest, revenue share of about 29% by the end of 2036. The market’s expansion can be attributed majorly to the soaring prevalence of different chronic diseases and prolonged pain, ache and infection among the people living in the region. According to studies across Asia, the prevalence of chronic pain in adults has been reported to vary greatly, ranging from 7% in Malaysia to 60% in Cambodia and Northern Iraq. Older adults are more likely to experience chronic pain, with prevalence rates as high as 40% to 90%. Additionally, the rising focus on health and fitness coupled with government initiatives which promote a healthy lifestyle is anticipated to increase the adoption rate of Oculopharyngeal muscular dystrophy. These factors are estimated to expand the market size in the forecast period.

Research Nester
Oculopharyngeal Muscular Dystrophy (OPMD) Market Size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5825
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The oculopharyngeal muscular dystrophy market growth is owing to factors like expanding geriatric population, introduction of new therapies, and increase in healthcare expenditure.

The market size of oculopharyngeal muscular dystrophy market is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024-2036.

The major players in the market are, Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc., Marathon Pharmaceuticals, Fibrinogen, GSK and others.

The symptomatic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample